LCI133

LCI133 is an innovative, highly potent, and selective multi-target kinase inhibitor effective at the nanomolar level. It targets CDK4/6/9 and AURKA/B with IC50 values of 4.7/10.2/4.1 nM and 2.8/10.6 nM, respectively. In MYCN-amplified neuroblastoma BE (2) -C cells, LCI133 induces S/G2 phase arrest and triggers significant apoptosis (apoptosis) . Moreover, LCI133 demonstrates substantial antitumor efficacy in BE (2) -C neuroblastoma xenograft models.